Glioma
Conditions
Interventions
WHO 1:temozolomide
WHO 1:Low dose
WHO 1:High dose
WHO 2:temozolomide
WHO 2:Low dose
WHO 2:High dose
WHO 3:temozolomide
WHO 3:Low dose
WHO 3:High dose
WHO 4: temozolomide
WHO 4:Low dose
WHO 4:High dose
Sponsors
Department of Experimental Zoology, Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18 to 70 years old patients with primary and recurrent gliomas; 2. Patients during the whole follow-up period (about 14 months) can and are willing to complete the whole specified study plan; 3. Patients / or patients' legal guardian or trustee have the ability to understand the research procedures, sign the informed consent voluntarily after informed consent, and can comply with the requirements of the clinical research program.
Exclusion criteria
Exclusion criteria: 1. Radiotherapy and chemotherapy patients; 2. The researchers judged that other conditions were not suitable for the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of HOXD11 in glioma; | — |
Countries
China
Contacts
Public ContactLiu Jia
Kunming Medical University
Outcome results
None listed